Antithrombotic agents in the treatment of severe sepsis

Expert Opinion on Emerging Drugs

Volumn 7, Issue 1, 2002, Pages 111-139

  Iqbal, Omer ^a   Messmore, Harry ^a   Fareed, Jawed ^a   Ahmad, Sarfraz ^a   Hoppensteadt, Debra ^a   Shadid, Hazar ^a   Tobu, Mahmut ^a   Aziz, Salim ^a   Wehrmacher, William ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Activated protein C; Antithrombin; Inflammatory mediators; Microvascular thrombosis; Severe sepsis; Thrombin activatable fibrinolytic inhibitor; Thrombomodulin; Tissue factor pathway inhibitor

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; ARACHIDONIC ACID; ARGATROBAN; BRADYKININ; CELL ADHESION MOLECULE; CGP 16056; COMPLEMENT; CYTOKINE; ENDOTOXIN; ENOXAPARIN; HIRUDIN; HISTAMINE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NITRIC OXIDE; PENTASACCHARIDE; PROSTAGLANDIN; REACTIVE OXYGEN METABOLITE; RECOMBINANT THROMBOMODULIN; THROMBOCYTE ACTIVATING FACTOR; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; XIMELAGATRAN;

ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING; CAUSE OF DEATH; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CRITICAL ILLNESS; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG MECHANISM; DRUG TARGETING; HUMAN; MEDIATOR RELEASE; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SEPSIS; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT FAILURE;

EID: 0036074964     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.7.1.111     Document Type: Review

References (334)

1. New hope for sepsis
2. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
3. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome and associated costs of care
4. Incidence of sepsis in US continues to rise
5. Sepsis: A new hypothesis for pathogenesis of the disease process
6. The natural history of the systemic inflammatory response syndrome (SIRS): A prospective study
7. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin
8. E5 murine monoclonal antiendo toxin antibody in Gram-negative sepsis: A randomized controlled trial
9. Increase in National Hospital Discharge Survey rates for septicaemia - United States, 1979-1987
10. Age-specific incidence and outcome of sepsis in the US
11. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with Gram-negative peritonitis
12. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14
13. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into the possible mechanism of action
14. Modulation of endothelium by heparin and related polyelectrolytes
15. New therapies in sepsis
16. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage
17. A natural anticoagulant pathway. Biochemistry and physiology of protein C, S C4b-binding protein and thrombomodulin
18. Protein S and c4b-binding protein. Components involved in the regulation of the protein C, anticoagulant system
19. The protein C pathway
20. Transactivated expression of fully γ-carboxylated recombinant human protein C, antithrombotic factor
21. Use of protein C concentrate, heparin, and haemofiltration in meningococcus-induced purpura fulminans
22. Meningococcemia and purpura fulminans in adults: Acute deficiencies of protein C and S and early treatment with antithrombin III concentrates
23. Treatment of purpura fulminans in meningococcemia with protein C concentrate
24. Protein C concentrate for meningococcal purpura fulminans
25. Protein C in the treatment of coagulopathy in meningococcal disease
26. The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis
27. Immunological therapy of sepsis: Experimental therapies
28. Role of coagulation inhibitors in inflammation
29. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin
30. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation
31. Emerging anticoagulant and thrombolytic drugs
32. Efficacy and safety of recombinant human activated protein C for severe sepsis
33. Report of the International Meeting on Intensive Care Medicine, Rome, Italy, October 1-4, 2000
34. Early events in the formation of a venous thrombus following local trauma and stasis
35. The biology of P-selectin glycoprotein ligand-1: Its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction
36. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets
37. Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulant therapy
38. Thrombin receptor function and cardiovascular disease
39. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: A juxtacrine system for adhesion and activation of neutrophils
40. New potential therapeutic modalities: Tissue factor pathway inhibitor
41. Therapeutic rationale for antithrombin III in sepsis
42. Inflammation and coagulation: Linked processes potentially regulated through a common pathway mediated by protein C
43. EPCR plays an important role in protein C activation in vivo
44. Factor Vlla and antithrombin III activity during severe sepsis and septic shock in neutropenic patients
45. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia
46. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells
47. Antithrombin reduces ischaemia/perfusion injury of rat liver by increasing the hepatic level of prostacyclin
48. Antithrombin III (ATIII) prevents LPS-induced vascular injury: Novel biological activity of ATIII, Thromb
49. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischaemia/ perfusion
50. Sulfated polysaccharide- directed recruitment of mammalian host proteins: A novel strategy in microbial pathogenesis
51. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli
52. Coagulation inhibitor substitution during sepsis
53. Septic shock, multiple organ failure and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C and protein S deficiencies
54. Therapeutic applications of antithrombin concentrates in systemic inflammatory disorders
55. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled double-blind, randomized multicenter study
56. Antithrombin replacement in patients with sepsis and septic shock
57. Regulation of coagulation by a multivalent kunitz-type inhibitor
58. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions
59. Tissue factor pathway inhibitor: Potential therapeutic applications
60. The effect of two-domain tissue factor pathway on endotoxin-induced disseminated intravascular coagulation in rabbits
61. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock
62. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon Gramnegative model of septic shock
63. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with Gram-negative peritonitis
64. Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock
65. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14
66. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxaemia
67. Tissue factor and factor X-dependent activation of protease-activated receptor 2 by factor VIIa
68. Coagulation factors VII and X induce calcium oscillations in Madin-Darby canine kidney cells only when proteolytically active
69. Coagulation factors VIIa and Xa induce cell signalling leading to upregulation of the egr-1 gene
70. Factor VIIa-induced p44/ 42 mitogen-activated protein kinase activation requires the proteolytic activity of factor VIIa and is independent of the tissue factor cytoplasmic domain
71. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages
72. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate
73. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency
74. Use of endothelium cultured on microcarriers as a model for the circulation
75. The roles for protein C and thrombomodulin in the regulation of blood coagulation
76. The endothelial cell protein C receptor augments protein C activation by thrombin-thrombomodulin complex
77. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor
78. Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor
79. Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine receptor enhances protein C activation
80. The endothelial cell protein C receptor: Inhibition of activated protein C anticoagulant function without modulation of reaction with protease inhibitors
81. Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function
82. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa
83. A model for thrombin protection against endotoxin
84. Activated protein C prevents E. coli induced coagulopathy and shock in the primate
85. C4b-binding protein exacerbates the host response to Escherichia coli
86. The endoth elial cell protein C receptor aids in host defense against Escherichia coli sepsis
87. Selective inhibitory effects of the anticoagulant activated protein C on the response of human mononuclear phagocytes to LPS, IFN-gamma or phorbol ester
88. Activated protein C reduces the ischaemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation
89. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production
90. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes
91. Binding of activated protein C to a specific receptor on human mononuclear phagocyte inhibits intracellular calcium signalling on monocyte dependent proliferative responses
92. Endothelial cell protein C receptor (EPCR) constitutively translocates into the nucleus and also mediates activated protein C but not protein C, nuclear translocation
93. Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner
94. Antithrombotic and anti-inflammatory agents of the protein C anticoagulant pathway
95. The anticoagulant and anti-inflammatory roles of protein C anticoagulant pathway
96. The profibrinolytic effect of activated protein C in clots formed from plasma in TAFI-dependent blood
97. Direct detection of activated protein C in blood from human subjects
98. Generation of activated protein C during thrombolysis
99. A sensitive and facile assay for the measurement of activated protein C activity levels in vivo
100. Development of the hemostatic system in the neonate and young infant
101. Prothrombin and protein C in early childhood. Normal adult levels are not achieved until the fourth year of life
102. Absence of thrombosis in subjects with heterozygous protein C deficiency
103. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock
104. Contribution of plasma protease inhibitors to the regulation of activated protein C in plasma
105. Inhibition and complexation of activated protein C by two major inhibitors in plasma
106. Activation of protein C and its distribution between its inhibitors, protein C inhibitor, α-1 antitrypsin and α-2 macroglobulin in patients with disseminated intravascular coagulation
107. Correlates of antithrombin,protein C, protein S and TFPI in a healthy elderly cohort
108. Protein C activity in healthy volunteers. Influence of age, sex, smoking and oral contraceptives
109. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases
110. Ageing-associated changes in indices of thrombin generation and protein C activation in humans. Normative ageing study
111. Quantification of circulating activated protein C in human plasma by immunoassays: Enzyme levels are proportional to total protein C levels
112. Molecular events that control the protein C anticoagulant pathway
113. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates
114. Circulating activated protein C in subjects with heterozygous Gln506-factorV
115. Brain-specific protein C activation during carotid artery occlusion in Humans
116. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes
117. Activated protein C correlates inversely with thrombin levels in resting healthy individuals
118. Association of plasma levels of activated protein C with recanalization of the infarct-related coronary artery after thrombolytic therapy in acute myocardial infarction
119. Inflammation and thrombosis: Mutual regulation by protein C
120. Cytokines and anticytokines in the pathogenesis of sepsis
121. Neutrophil and endothelial cell interactions in sepsis
122. Safety and dose-relationship of recombinant human activated protein C (rhAPC) on coagulopathy in severe sepsis
123. Prognostic value of protein C levels in neutropenic patients at high risk of severe septic complications
124. Efficacy and safety of recombinant human activated protein C for treatment of patients with severe sepsis
125. Low levels of protein C are associated with poor outcome in severe sepsis
126. Time course of hemostatic abnormalities in sepsis and its relation to outcome
127. Protein C in the treatment of coagulation in meningococcal sepsis
128. Meningococcal septicemia: Treatment with protein C concentrate
129. The use of protein C in severe meningococcal sepsis
130. Description of compensated and uncompensated disseminated intravascular coagulation (DIC) responses (non-overt and overt DIC) in baboon models of intravenous and intraperitoneal Escherichia coli sepsis and in human model of endotoxaemia: Toward a better definition of DIC
131. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro
132. Tumour necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture
133. Regulation of thrombomodulin by tumour necrosis factor-alpha: Comparison of transcriptional and post-translational mechanisms
134. Modulation of human endothelial thrombomodulin by neutrophils and their release products
135. Thrombomodulin: An overview and potential implications in vascular disorders
136. Relationships between plasma levels of Type II phospholipase A2, PAF-acetylhydrolase, leukotriene B4, complements, endothelin-1 and thrombomodulin in patients with sepsis
137. Increased circulating thrombomodulin in children with septic shock
138. Soluble thrombomodulin increases in patients with disseminated intravascular coagulation and in those with multiple organ dysfunction syndrome after trauma: Role of neutrophil elastase
139. Cytokines, soluble thrombomodulin and disseminated intravascular coagulation in patients with systemic inflammatory response syndrome
140. Increased plasma levels of soluble thrombomodulin in patients with sepsis and organ failure
141. Endothelial cell and hemostatic activation in relation to cytokines in patients with sepsis
142. Expression of tissue factor, thrombomodulin and E-selectin in baboons with lethal E. coli sepsis
143. Lack of suppressed renal thrombomodulin expression in a septic rat model with glomerular thrombotic microangiopathy
144. Molecular mechanism of thrombosis in meningococcal septicaemia: The role of the protein C pathway in vivo
145. Treatment of purpura fulminans in meningococcemia with protein C concentrate
146. Infectious purpura fulminans. Diagnosis and treatment
147. Recombinantthrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation
148. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent
149. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation
150. Activation and characterization of procarboxy peptidase B from human plasma
151. Isolation, molecular cloning and partial characterization of a novel carboxypeptidase B from human plasma
152. Purification and characterization of a new arginine carboxypeptidase in human serum
153. Plasma and recombinant thrombin-activatable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/ thrombomodulin dependent activation, thermal stability and enzymatic properties
154. A carboxypeptidase inhibitor from the medicinal leech Hirudo medicinalis-isolation, sequence analysis, cDNA cloning, recombinant expression and characterization
155. Activated human plasma carboxypeptidase B is retained in the blood by binding to α-2 macroglobulin and pregnancy zone protein
156. Characterization and plasmin mediated activation of plasma procarboxypeptidase B - Modulation by glycosaminoglycans
157. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activatable fibrinolysis inhibitor
158. Isolation, molecular cloning and partial characterization of a novel carboxypeptidase B from human plasma
159. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor
160. Plasma carboxypeptidase as regulators of the plasminogen system
161. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor
162. Procarboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not
163. Molecular cloning and partial characterisation of rat procarboxypeptidase N
164. Plasma thrombomodulin in health and disease
165. Protein C activation on endothelial cells by prothrombin activation products generated in situ: Meizothrombin is a better protein C activator than alpha thrombin
166. Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation
167. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
168. Selective cellular expression of tissue factor in human tissues
169. Protection of factor Xa from neutralization by heparin antithrombin complex
170. Properties of factor Xa binding site on platelets
171. Low molecular weight heparins
172. Oral delivery of heparin in combination with sodium N-(2-hydroxybenzoyl]amino) caprylate: Pharmacological considerations
173. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind controlled study in humans
174. Orally administered heparin for preventing deep vein thrombosis
175. Insight into the mechanism of action of heparin cofactor II
176. Dermatan sulfate for the prevention of postoperative venous thrombosis in patients with cancer
177. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin
178. Role of endothelial cell surface heparin-like polysaccharides
179. Pharmacology of sulfomucopolysaccharides in atherosclerotic prevention and treatment
180. An overview of nonheparin glycosaminoglycans as antithrombotic agents
181. Heparan sulfate: Efficacy and safety in patients with chronic venous insufficiency
182. Effectiveness of short-term suledoxide treatment on peripheral vascular disease clinical manifestations
183. Thromboprophylaxis in patients with hip fractures. A prospective, randomized, comparative study between Org 10 172 and dextran 70
184. A controlled clinical experiment 'within subjects' with heparan sulfate in intermittent claudication
185. Dermatan sulfate in hemodialysis
186. Dermaran sulfate in acute leukaemia
187. Fibrin monomer protects thrombin from inactivation by heparin:antithrombin III: Implications for heparin efficacy
188. Clot-bound thrombin is protected from inhibition by thrombin-antithrombin III but is susceptible to inactivation by antithrombin III-dependent inhibitors
189. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by anti thrombin-independent inhibitors
190. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4
191. Cloning and expression of cDNA coding for the anticoagulant hirudin from blood sucking leech, Hirudo medicinalis
192. Kinetics of inhibition of thrombin by hirudin
193. Hirudins: Antithrombotic anticoagulants
194. Use of recombinant hitudin as antithrombotic treatment in patients with heparin-induced thtombocytopenia
195. Hirudin therapy for heparin-associated thrombocytopenia and deep venous thrombosis
196. New treatment options for heparin-induced thrombocytopenia
197. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man
198. Recombinant hirudin as an anticoagulant in open-heart surgery: A case report
199. Prevention of deep vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393
200. A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement
201. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischaemia without ST elevation: A pilot study
202. Effects of recombinant hirudin (lepirudin) compared with heparin in patients with acute myocardial ischaemia without ST elevation: A randomized trial
203. Successful use of recombinant hirudin for anticoagulation and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing cardiac bypass surgery (Abstract)-Session XVII: perfusion/Cardiac Tumours
204. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors on thrombin
205. Thrombin-specific inhibition by and slow cleavage of hirulog-1
206. Anticoagulant activity of hirulog, a direct inhibitor of thrombin
207. Hirulog: A direct thrombin inhibitor for management of acute coronary syndromes
208. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina
209. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina
210. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction
211. Argatroban: A synthetic thrombin inhibitor of low relative molecular mass
212. Results of Phase II/3 trial of argatroban anticoagulation during PTCA of patients with heparin-induced thrombocytopenia (HIT)
213. A randomized study of argatroban versus heparin as adjunctive therapy to tissue plasminogen activator in acute myocardial infarction: MINT (Myocardial infarction with Novastan and tPA) Study
214. Single and repeated oral dosing of H376/95, a prodrug for the direct thrombin inhibitor, melagatran, to young healthy male subjects
215. Pharmacodynamic properties of H376/95, a prodrug of the direct thrombin inhibitor, melagatran, intended for oral use
216. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation and its stable N-methy derivative
217. The kinetics of reversible tight-binding inhibition
218. Design and synthesis of potent and highly selective thrombin inhibitors
219. Phase I studies on inogatran, a new selective thrombin inhibitor
220. Active-site blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model
221. Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats
222. An inhibitory antifactor IX-antibody effectively reduces thrombus formation in a rat model of venous thrombosis
223. A monoclonal antibody to factor IX that inhibits the factor VIII:Ca potentiation of factor X activation
224. Biochemical and pharmacological properties of SANORG 34006, a potent and long acting synthetic pentasaccharide
225. Heparin
226. Structural and functional characterization of a tick anticoagulant peptide (TAP): A potent and selective inhibitor of blood coagulation factor Xa
227. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high antifactor Xa activity
228. Total synthesis of a heparin pentasaccharide fragment having high affinity for antithrombin III
229. Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide 0-(2-deoxy-2-sulfamido-6- O-sulfo-alpha-LD-glucopyranosyl)-1→4)- 0-(beta-D-glucopyranosyluronic acid)- (1→4)-0-(2-deoxy-2-sulfamido-3,6-di-0- sulfo-alpha-L-idopyranosyluronic acid)- (1→4)-2-deoxy-2-sulfamido-6-O-sulfo-D-glucopyranose decasodium salt
230. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges
231. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole antifactor Xa activity
232. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (Pentasaccharide) in rats
233. Fareed: Heparinase neutralization of low molecular weight heparins
234. Isolation and characterization of antistatin
235. Antistatin, a leech-derived inhibitor of factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site
236. FXa inhibitor from the saliva of the leech Hirudo medicinalis
237. Reaction pathway for inhibition of blood coagulation factor Xa by tick anticoagulant peptide
238. Tick anticoagulant peptide: Kinetic analysis of the recombinant inhibitor with blood coagulation factor Xa
239. DX-9065a, a novel, synthetic, selective and orally-active inhibitor of factor Xa: In vitro and in vivo studies
240. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally-active inhibitor of human factor Xa
241. Nonpeptide factor Xa inhibitors. I. Studies with SF303 and SK549, a new antithrombotic
242. Design and synthesis of isoxazoline derivative as factor Xa inhibitors
243. Molecular and cellular biology of blood coagulation
244. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into the possible mechanism of action
245. Modulation of endothelium by heparin and related polyelectrolytes
246. Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: Potential mechanisms for heightened prothrombotic potential
247. Tissue factor pathway inhibitor
248. Ancylostoma caninum anticoagulant peptide: A hookworm derived inhibitor of human coagulation factor Xa
249. Anticoagulant repertoire of hematophagous nematodes
250. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C
251. Thrombomodulin blocks the ability of thrombin to activate platelets
252. The roles of protein C and thrombomodulin in the regulation of blood coagulation
253. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme
254. Structure and expression of human rhrombomodulin, a thrombin receptor on endothelium acting as a cofactor of protein C activation
255. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice
256. Stable expression of a secreatable deletion mutation and recombinant human thrombomodulin in mammalian cells
257. Antithrombotic effects of recombinant human soluble thrombomodulin in a rat model of vascular shunt thrombosis
258. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravscular coagulation with decreased levels of plasma antithrombin III
259. Antithrombotic effect of recombinant soluble thrombomodulin on disseminated intravascular coagulation
260. A natural anticoagulant pathway. Biochemistry and physiology of proteins C, S, C4b-binding protein and thrombomodulin
261. Protein S and c4b-binding protein. Components involved in the regulation of the protein C anticoagulant system
262. The protein C pathway
263. Transactivated expression of fully γ-carboxylated recombinant human protein C, antithrombotic factor
264. TAFI or plasma procarboxipeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
265. On the mechanism of antifibrinolytic activity of plasma carboxypeptidase B
266. Inducible carboxypeptidase activity: A role in clot lysis in vivo
267. A novel approach to arterial thrombolysis
268. The roles of fibrinogen and fibrin in haemostasis and thrombosis
269. Tridegin, a novel peptide inhibitor of factor XIIIa from the leech, Haementeria ghilianii, enhances fibrinolysis in vitro
270. Tridegin, a new peptide inhibitor of factor XIIIa, from the blood sucking leech, Haementeria ghilianii
271. Destabilase, the novel epsilon-(gamma-Glu)-Lys isopeptidase with thrombolytic activity
272. Genes from the medicinal leech (Hirudo medicinalis) coding for unusual enzymes that specifically cleave endo-epsilon (gamma-Glu)-Lys isopeptide bonds and help to dissolve blood clots
273. Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil
274. Attenuation of the synthesis of plasminogen activator inhibitor Type 1 by niacin: A potential link between lipid lowering and fibrinolysis
275. The acid stabilization of plasminogen activator inhibitor 1 depends on the protonation of a single group that affects loop insertion into β-sheet A
276. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro
277. Novel low molecular weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces post-thrombolysis thrombus growth in rabbits
278. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents
279. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty: The EPIC Investigators
280. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization: The EPILOG Investigators
281. Complementary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein Iib/ IIIa receptors. Evaluation of platelet IIb/IIIa inhibition in Stenting Investigators
282. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrelin therapy
283. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms. Inhibition of the platelet glycoprotein IIb/IlIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
284. Platelet receptor Inhibition in ischemic syndrome management. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
285. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A pooled analysis of the large scale oral glycoprotein lIb/IIIa trials
286. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet pre-eminence
287. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet pre-eminence
288. Platelet and thrombolytic therapy
289. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue type plasminogen activator and monoclonal antiplatlet GPIIb/IIIa antibody in a canine preparation
290. A randomized, placebo-controlled crossover trial of ReoPro alone or combined with low-dose plasminogen activator for coronary reperfusion in patients with acute myocardial infarction: Preliminary results
291. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial
292. Nitric Oxide: Physiology, pathophysiology and pharmacology
293. Calmodulin-dependent endothelium derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fraction of bovine aortic endothelial cells
294. Nitric oxide as a secretory product of mammalian cells
295. Antimicrobial and immunopathologic effects of cytokine-induced nitric-oxide synthesis
296. Peripheral vascular resistance in septic shock: Its relation to outcome
297. Southwestern Internal Medicine Conference: Septic shock
298. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharide in the rat in vivo
299. Dexamethasone prevents the induction by endotoxin of nitric oxide synthase and the associated effects on vascular tone: An insight into endotoxin shock
300. Induction and activity of nitric oxide synthase in cultured human intestinal epithelial monolayers
301. Potent inhibition of inducible nitric oxide synthase by geldanamycin, a tyrosine kinase inhibitor, in endothelial, smooth muscle cells and in rat aorta
302. Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: A possible role for protein tyrosine kinase
303. Serine and cysteine protease inhibitors prevent nitric oxide production by activated macrophages by interfering with transcription of the inducible NO synthase gene
304. Role of transcription factor NF-(B/Rel) in induction of nitric oxide
305. Chracterization of the Larginine: Nitric oxide pathways in human platelets
306. The inducible nitric oxide synthase is impaired by thrombin in vascular smooth muscle cells
307. Interleukin-13 alters the activation state of murine macrophages in vitro: Comparison of interleukin-4 and interferon-gamma
308. Endothelin-1 inhibits induction of nitric oxide synthase and GTP cyclohydolase I in rat mesangial cells
309. Interleukin-13 inhibits inducible nitric oxide synthase expression in human mesangial cells
310. Attenuation by calpain inhibitor 1, an inhibitor of the proteolysis of IκB, of the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat
311. Glucocorticoids inhibit the expression of an inducible but not the constitutive, nitric oxide synthase in vascular endothelial cells
312. Nuclear factor kappaB: A pivotal transcription factor in chronic inflammatory diseases
313. Sepsis Research: We must change course
314. A comparison of risks and outcomes for patients with organ system failure: 1982-1990
315. Neugebauer: Sepsis research in the next millennium: Concentrate on the software rather than the hardware
316. Sepsis, signals and surgical sequelae (a hypothesis)
317. Sir Isaac Newton, sepsis, SIRS and CARS
318. Uncoupling of biological oscillators: A complementary hypothesis concerning the pathogenesis of multiple organ dysfunction syndrome
319. Protease activated receptors start a family
320. Factor Xa-inhibitor (DX 9065a) modulates the leukocyte-endotheial cell interaction in endotoxaemic rat
321. Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo
322. Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates pro thrombinase-catalyzed thrombin generation. (1997)
323. In vivo immunosuppression by targeting a novel protease receptor
324. Human umbilical vein endothelial cells express high affinity receptors for factor Xa
325. Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells
326. Influence of Low Molecular Weight Heparin (Certoparin) and Unfractionated Heparin on the release of cytokines from human leukocytes
327. Characterization of the heparin-binding properties
328. Low Molecular Weight Heparin inhibits tumour necrosis factor αinduced leukocyte rolling
329. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery
330. Beneficial effect of JTV-803, a new synthetic inhibitor of activated factor X, against both lipopolysaccharide-induced and tissue facto-induced disseminated intravascular coagulation in rat models
331. Antithrombotic effects of a synthetic inhibitor of activated factor X, JTV-803, in animals
332. Inhibitory effect of JTV-803, a new cyclic guanidine derivative, on factor Xa in vitro and in vivo
333. In vitro effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests